Biological agents for the treatment of ankylosing spondylitis include adalimumab, infliximab, golimumab, and etanercept. Biological agents such as adalimumab, infliximab, golimumab, and etanercept belong to the tumor necrosis factor TNF-α antagonists, which have strong anti-inflammatory effects, but long-term use of the drug may increase the risk of tuberculosis, hepatitis, and neoplasms, as well as lead to optic neuritis, congestive heart failure, and other diseases. Close monitoring of adverse drug reactions is required. Patients suffering from tumors, tuberculosis, hepatitis and other diseases need to use the drug with caution. It is recommended that patients go to the rheumatology and immunology department of regular hospitals for detailed consultation and follow the doctor’s instructions to use the drug.